Maturing pipeline of next-generation therapeutic innovations including antibodies, bispecific antibodies, small molecules, vaccines and cell therapeutics
QIMR Berghofer is developing therapeutic interventions for a number of disease areas, including oncology, infectious disease and autoimmune disorders. These exciting new technologies use cutting-edge modalities such as bi-specific antibodies and cellular therapies.
Breast cancer is the leading cause of female cancer deaths worldwide and with an estimated 1.7 million new cases every year. The histone methyltransferase enzyme G9a is over expressed in many malignancies, including breast cancer, and effects regulation of genes involved in tumour progression. G9a is also an epigenetic regulator of the known oncogene MYC; long viewed as a potential target for novel therapeutics. QIMR Berghofer researchers, in partnership with drug discovery CRO Domainex, have developed a small molecule inhibitor of G9a which shows promising in vitro and in vivo efficacy against breast cancer. We have demonstrated that tumours derived from tamoxifen resistant cell lines are resensitized to tamoxifen when combined with a G9a inhibitor, with the combination inducing tumour regression.